Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

April 29, 2026 updated by: Orano Med LLC

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

In this open-label, dose escalation and dose expansion single ascending dose (SAD) and multiple ascending dose (MAD) phase 1 study, participants with recurrent or metastatic histologically confirmed GRPR-expressing tumors will be enrolled. In the dose escalation portion, a classic 3+3 design will be utilized for the SAD cohorts and a BOIN design for the MAD cohorts. Dose escalation may proceed until the recommended MAD dose is determined. Up to six (2 SAD and 4 MAD) cohorts are expected to be enrolled. Participants will be treated with up to four cycles administered every 4 or 6 weeks. Once the recommended MAD dose is determined, the expansion cohorts of the study will commence. A dosimetry sub study will also be conducted in participants part of the dose escalation.

Study Type

Interventional

Enrollment (Estimated)

48

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Active, not recruiting
        • Northwestern University Robert H Lurie Medical Research
    • Kentucky
      • Lexington, Kentucky, United States, 40536
        • Recruiting
        • UK Markey Cancer Center
        • Principal Investigator:
          • Eddy Yang, MD
        • Contact:
          • Phone Number: 859-323-7628
    • Maryland
      • Glen Burnie, Maryland, United States, 21061
        • Recruiting
        • Advanced Molecular Imaging and Therapy
        • Principal Investigator:
          • Michael Morris, MD
        • Contact:
          • Phone Number: 443-333-1894
    • Nebraska
      • Omaha, Nebraska, United States, 68130
        • Recruiting
        • XCancer Omaha / Urology Cancer Center
        • Principal Investigator:
          • Luke Nordquist, MD
        • Contact:
          • Phone Number: 402-697-2229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

  1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis):

    1. Metastatic castration-resistant prostate cancer (mCRPC) including neuroendocrine prostate cancer (NEPC) (enrolled only in SAD and MAD Q6W)
    2. HR+/HER2- breast cancer (estrogen receptor/ER expression >10% of tumor cell nuclei stain, regardless of progesterone receptor/PgR expression); HER2-negative including HER2-low (as per relevant ASCO/CAP guidelines)
    3. Colorectal cancer
    4. Cervical cancer
    5. Non-small-cell lung cancer (NSCLC)
    6. Recurrent glioblastoma (only enrolled in MAD Q4W cohorts) with evidence of recurrent disease (RD) demonstrated by disease progression using modified Response Assessment in Neuro-Oncology (RANO 2.0) criteria. Note: If surgery is performed for GBM recurrence, pre-surgery MRI will be used for confirmation of RD and residual and measurable disease post-surgery is not required but surgery must have confirmed the recurrence diagnosis by MRI.
  2. Capable of giving signed informed consent
  3. All participants must have progressed on at least 2 prior systemic therapies, except for recurrent GB
  4. For participants with mCRPC: Prior orchiectomy and/or ongoing androgen deprivation therapy and a castrate level of serum testosterone (<50 ng/dL or <1.7 nmol/L)
  5. Presence of at least 1 measurable lesion per RECIST 1.1 as assessed by the Investigator (not applicable for GBM). At least 1 identified measurable lesion must show GRPR uptake in 203Pb-DOTAM-GRPR1 SPECT/CT (uptake greater than that of the background) as assessed by the Investigator.
  6. For participants with prostate cancer that do not have measurable soft tissue disease, 203Pb-DOTAM-GRPR1 uptake in bone lesions > uptake in background is acceptable for eligibility.
  7. Eastern Cooperative Oncology Group (ECOG) status 0-1. Participants with ECOG status of 2 may be approved on a case-by-case basis in discussion with the Sponsor.

  8. Adequate bone marrow, hepatic, and renal function, as assessed by the following laboratory requirements:

    1. White blood cell (WBC) ≥3000/ mm3 (≥ 3 x 109/L)
    2. Absolute neutrophil count (ANC) ≥1500/mm3 (≥1.5 x 109/L)
    3. Platelets ≥100,000/mm3 (≥ 100 x 109/L)
    4. Hemoglobin (Hb) ≥9.0 g/dL
    5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3x upper limit of normal (ULN) or ≤ 5 x ULN in the presence of liver metastases
    6. Total bilirubin: ≤1.5 x ULN, except if documented history of Gilbert's disease who are eligible if total bilirubin ≤ 3 x ULN
    7. Adequate renal function defined by creatinine clearance (CLCR) ≥ 60 mL/min calculated as follows: CLCR = eGFR in ml/min/1.73 m2 calculated by the Modified Diet in Renal Disease (MDRD) x participant body surface area (BSA) in m2 ÷ 1.73
    8. Serum amylase and/or lipase ≤1.5 x ULN

  9. For women of childbearing potential (WOCBP) and men with partners of childbearing potential: be willing to use highly effective methods of contraception or sexual abstinence, if part of participant's lifestyle, throughout the study and for 7 months for WOCBP, 4 months for men after the last [212Pb]Pb-DOTAM-GRPR1 administration or for 10 days following [203Pb]Pb-DOTAM-GRPR1 administration and participant is not proceeding to 212Pb-DOTAM-GRPR1 treatment, as outlined in protocol.

    Participants with Recurrent Glioblastoma:

  10. Having first or second glioblastoma recurrence, after standard therapy that includes prior radiation therapy (RT) and at least 12 weeks from completion of RT prior to first administration of 212Pb-DOTAM-GRPR1. In case surgery has been performed for GBM recurrence, the surgery has to be completed at least 4 weeks prior to 212Pb-DOTAM-GRPR1 treatment start, with post-surgery recovery without any complications related to surgical procedure.
  11. Presence of 203Pb-DOTAM-GRPR1 uptake by SPECT/CT scan in the tumor lesion(s).
  12. Presence of Gadolinium enhancement in the MRI in the tumor lesion(s) shown at the time of diagnosis of tumor recurrence.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ²¹²Pb-DOTAM-GRPR1
In the dose escalation portion, a classic 3+3 design will be utilized for the SAD cohorts and a Boin design for the MAD cohorts. Doses will be increased by approximately 30% in subsequent cohorts. The maximum total dose that may be administered to a subject per cycle is 5.5 mCi +/- 10%.
Drug: ²¹²Pb-DOTAM-GRPR1
²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To determine the Recommended Phase 2 Dose (RP2D) of ²¹²Pb-DOTAM-GRPR1
Time Frame: 14 months
Incidence of DLTs.
14 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess the safety and tolerability of 212Pb-DOTAM-GRPR1.
Time Frame: 24 months
Measured as Incidence and severity of TEAEs and TESAEs.
24 months
To assess the safety and tolerability of 203Pb-DOTAM-GRPR1.
Time Frame: 24 months
Measured as Incidence and severity of TEAEs and TESAEs.
24 months
To assess PK of ²¹²Pb-DOTAM-GRPR1
Time Frame: 24 months
212Pb-DOTAM-GRPR1 radioactivity concentration as a function of time in whole blood, plasma and urine
24 months
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1.
Time Frame: 24 months
ORR by RECIST1.1, DOR, PFS by Investigator assessment and OS.
24 months
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1
Time Frame: 24 months
For participants with mCRPC, by Investigator assessment of ORR which is defined as a proportion of participants having a 'best overall response' (BOR) assessment of Complete Response (CR) or Partial Response (PR) as per PCWG3 guidelines.
24 months
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1
Time Frame: 24 months
For participants with mCRPC, by Investigator assessment of DOR which is defined as the time from the first documented objective response of PR or CR by PCWG3, whichever occurs earlier, to disease progression or death.
24 months
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1
Time Frame: 24 months
For participants with mCRPC, by Investigator assessment of PFS which is defined as the time from the start of study intervention to the date of first observed disease progression (Investigator's radiological assessment), clinical disease progression (Investigator's assessment) or death due to any cause as per PCWG3 guidelines.
24 months
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1
Time Frame: 24 months
For participants with mCRPC, as Overall Survival (OS) is defined as the time from the date of the start of study intervention to the date of death due to any cause.
24 months
To evaluate the preliminary antitumor activity of 212-PbDOTAM-GRPR1.
Time Frame: 24 Months
For participants with recurrent GBM, by Investigator assessment of ORR which is defined as a proportion of participants having a 'best overall response' (BOR) assessment of Complete Response (CR) or Partial Response (PR) as per RANO 2.0 criteria.
24 Months
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1.
Time Frame: 24 months
For participants with recurrent GBM, by Investigator assessment of DOR defined as the time from the first documented objective response of PR or CR by RANO v 2.0, whichever occurs earlier, to disease progression or death
24 months
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1.
Time Frame: 24 months
For participants with recurrent GBM, Investigator assessment of PFS defined as the time from the start of study intervention to the date of first observed disease progression (Investigator's radiological assessment), clinical disease progression (Investigator's assessment) or death due to any cause as per RANO 2.0 criteria.
24 months
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1.
Time Frame: 24 months
For participants with recurrent GBM, Overall Survival (OS) is defined as the time from the date of the start of study intervention to the date of death due to any cause.
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Orano Med LLC

Investigators

  • Study Director: Jason D Hurt, MD, Orano Med

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 22, 2022

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

May 1, 2032

Study Registration Dates

First Submitted

February 13, 2022

First Submitted That Met QC Criteria

March 11, 2022

First Posted (Actual)

March 16, 2022

Study Record Updates

Last Update Posted (Actual)

April 30, 2026

Last Update Submitted That Met QC Criteria

April 29, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OM-GRPR1-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Clinical Trials on ²¹²Pb-DOTAM-GRPR1

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe